v3.26.3
Shareholders’ Equity (Deficit) (Details) - $ / shares
9 Months Ended
Sep. 30, 2026
Dec. 31, 2025
Shareholders’ Equity (Deficit) [Line Items]    
Preference shares, shares authorized 5,000,000 5,000,000
Preference shares, par value $ 0.0001 $ 0.0001
Preference shares, issued
Preference shares, outstanding
Subject to possible redemption 1  
Sponsor [Member] | Founder Shares [Member]    
Shareholders’ Equity (Deficit) [Line Items]    
Forfeited shares 771,429  
Class A Ordinary Shares [Member]    
Shareholders’ Equity (Deficit) [Line Items]    
Ordinary shares, authorized 485,000,000 485,000,000
Ordinary shares, par value $ 0.0001 $ 0.0001
Vote for each share one  
Ordinary shares, issued 326,875
Ordinary shares, outstanding 326,875
Subject to possible redemption 1  
Shares subject to possible redemption 13,800,000  
Class B Ordinary Shares [Member]    
Shareholders’ Equity (Deficit) [Line Items]    
Ordinary shares, authorized [1],[2] 10,000,000 10,000,000
Ordinary shares, par value [1],[2] $ 0.0001 $ 0.0001
Vote for each share one  
Ordinary shares, issued [1],[2] 5,914,286 5,914,286
Ordinary shares, outstanding [1],[2] 5,914,286 5,914,286
Over-Allotment Option [Member] | Class B Ordinary Shares [Member]    
Shareholders’ Equity (Deficit) [Line Items]    
Forfeited shares 771,429  
[1] At December 31, 2025, included an aggregate of 771,429 Class B ordinary shares subject to forfeiture if the over-allotment option was not exercised in full or in part by the underwriters. On January 30, 2026, the underwriters exercised their over-allotment option in full as part of the closing of the Initial Public Offering. As a result of the underwriters’ election to fully exercise their over-allotment option, 771,429 Founder Shares are no longer subject to forfeiture by the Sponsor (Note 5).
[2] On January 29, 2026, the Company issued an additional 985,715 Founder Shares to the Sponsor through a share capitalization, resulting in the Sponsor holding an aggregate of 5,914,286 Founder Shares. All share and per-share data have been retrospectively presented (Note 5).